PLGA-linked alendronate enhances bone repair in diaphysis defect model
- 3 June 2016
- journal article
- research article
- Published by Hindawi Limited in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 11 (9) , 2603-2612
Abstract
Alendronate (ALN) is known as an anti-resorptive drug for the treatment of osteoporosis. Recently, ALN was found to stimulate osteogenic differentiation in mesenchymal stem cells and enhance new bone formation in calvarial bone defects. Previous in vitro and in vivo studies found that the effective concentration of ALN was approximately 1–10 μm. In the present study, a poly (lactic-co-glycolic acid) (PLGA) cross-linked ALN (PLGA-ALN) with a short-term controlled-release property for local application to enhance bone repair was developed. An in vitro drug-release kinetic test showed that PLGA-ALN microspheres released an effective concentration (50–100 nm) of ALN for 9 days. The effect of PLGA-ALN on bone repair was tested in a rat femoral bone defect model. The biomechanical study results showed that the maximal strength, stiffness and energy absorption were significantly increased in the PLGA-ALN group compared with the PLGA group. The microstructure of the newly formed bone at the defect site was analysed using microcomputed tomography. The PLGA-ALN group significantly improved the trabecular bone volume at the defect site compared with the PLGA group. The fibril collagen and immunolocalized bone morphogenetic protein 2 were evident in the newly formed trabecular bone in the PLGA-ALN group. Local use of newly developed PLGA-ALN-enhanced bone repair was attributable to increasing bone matrix formation, which improved the ultrastructure of the newly formed bone and thus increased the biomechanical properties of the repaired bone. It is suggested that PLGA-ALN may be a potential bone graft substitute to enhance bone repair. Copyright © 2016 John Wiley & Sons, Ltd.Keywords
This publication has 28 references indexed in Scilit:
- Polysaccharides of Trametes versicolor Improve Bone Properties in Diabetic RatsJournal of Agricultural and Food Chemistry, 2015
- (−)-Epigallocatechin-3-gallate improves bone microarchitecture in ovariectomized ratsMenopause, 2013
- The bone architecture is enhanced with combined PTH and alendronate treatment compared to monotherapy while maintaining the state of surface mineralization in the OVX ratBone, 2011
- Controlled Release Scaffolds for Bone Tissue EngineeringJournal of Pharmaceutical Sciences, 2009
- A Review of the Development of a Vehicle for Localized and Controlled Drug Delivery for Implantable BiosensorsJournal of Diabetes Science and Technology, 2008
- Biocompatibility of poly(d,l-lactide-co-glycolide) nanoparticles conjugated with alendronateBiomaterials, 2008
- Alendronate Has an Anabolic Effect on Bone Through the Differentiation of Mesenchymal Stem CellsJournal of Bone and Mineral Research, 2007
- Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapiesOsteoporosis International, 2007
- Design of surface-modified poly(d,l-lactide-co-glycolide) nanoparticles for targeted drug delivery to boneJournal of Controlled Release, 2007
- Bisphosphonate treatment affects trabecular bone apparent modulus through micro‐architecture rather than matrix propertiesJournal of Orthopaedic Research, 2004